The Global Rise of Fake GLP-1 Medicines

Glucagon-like peptide-1 medicines, commonly referred to as GLP-1 medicines, represent one of the most consequential pharmaceutical breakthroughs of the past decade, initially transforming the treatment of Type 2 diabetes before rapidly demonstrating profound secondary benefits in weight loss, cardiovascular risk reduction, and broader metabolic health.

Branded products such as Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Rybelsus, and regional equivalents marketed across Europe, the United States, and other global markets moved quickly from specialty prescribing into mainstream use, driven by compelling clinical outcomes, unprecedented consumer demand, social media amplification, and the rapid expansion of direct-to-consumer telehealth distribution models.

That success, however, produced predictable market distortions and, with them, a dangerous secondary economy.

As demand for GLP-1 medicines outpaced legitimate supply, counterfeiters, illicit manufacturers, unscrupulous compounders, and organized criminal actors moved in, first within the US and then with increasing speed across Europe, Asia, Africa, and beyond.

Today, fake GLP-1 medicines represent a global patient safety threat that mirrors earlier counterfeit crises involving opioids, oncology therapies, and lifestyle drugs, though at a scale, velocity, and level of sophistication that exceeds prior precedent.